The efficacy of Eylea to treat proliferative diabetic retinopathy/preproliferative diabetic retinopathy in patients with diabetic macular edema

Trial Profile

The efficacy of Eylea to treat proliferative diabetic retinopathy/preproliferative diabetic retinopathy in patients with diabetic macular edema

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Diabetic retinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2016 Planned number of patients changed from 40 to 50.
    • 13 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top